Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1978 1
1989 1
1990 2
1992 1
1998 3
1999 1
2000 1
2001 1
2002 1
2003 3
2005 2
2006 1
2007 3
2008 2
2009 3
2010 14
2011 11
2012 10
2013 9
2014 10
2015 10
2016 10
2017 11
2018 16
2019 16
2020 16
2021 12
2022 9
2023 17
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Angioedema, hereditary, 8"
Page 1
Inhibition of Prekallikrein for Hereditary Angioedema.
Fijen LM, Riedl MA, Bordone L, Bernstein JA, Raasch J, Tachdjian R, Craig T, Lumry WR, Manning ME, Alexander VJ, Newman KB, Revenko A, Baker BF, Nanavati C, MacLeod AR, Schneider E, Cohn DM. Fijen LM, et al. N Engl J Med. 2022 Mar 17;386(11):1026-1033. doi: 10.1056/NEJMoa2109329. N Engl J Med. 2022. PMID: 35294812 Clinical Trial.
BACKGROUND: Hereditary angioedema is characterized by recurrent and unpredictable swellings that are disabling and potentially fatal. ...The mean change from baseline to week 17 in the Angioedema Quality of Life Questionnaire score was -26.8 points in …
BACKGROUND: Hereditary angioedema is characterized by recurrent and unpredictable swellings that are disabling and potentially …
Gene Mutations Linked to Hereditary Angioedema in Solitary Angioedema Patients With Normal C1 Inhibitor.
Bork K, Wulff K, Witzke G, Staubach P, Hardt J, Meinke P. Bork K, et al. J Allergy Clin Immunol Pract. 2023 Aug;11(8):2441-2449. doi: 10.1016/j.jaip.2023.01.051. Epub 2023 Feb 12. J Allergy Clin Immunol Pract. 2023. PMID: 36787826 Free article.
BACKGROUND: Chronic recurrent angioedema without wheals (CRA) with normal C1 inhibitor (C1-INH) that is unresponsive to antihistamines may involve patients with recurrent angioedema of unknown cause (ie, so-called non-histaminergic idiopathic angioedema) as w …
BACKGROUND: Chronic recurrent angioedema without wheals (CRA) with normal C1 inhibitor (C1-INH) that is unresponsive to antihistamine …
Recurrent angioedema in childhood: hereditary angioedema or histaminergic angioedema?
Ocak M, Nain E, Şahiner ÜM, Akin MŞ, Karabiber E, Şekerel BE, Soyer Ö. Ocak M, et al. Pediatr Dermatol. 2021 Jan;38(1):143-148. doi: 10.1111/pde.14467. Epub 2020 Dec 4. Pediatr Dermatol. 2021. PMID: 33275322
BACKGROUND: Recurrent angioedema is a rare entity during childhood. This study aimed to clarify differences between hereditary angioedema (HAE) and histaminergic angioedema (HA) in children. METHODS: Fifty-seven children with HAE (male 36.8%, …
BACKGROUND: Recurrent angioedema is a rare entity during childhood. This study aimed to clarify differences between hereditary …
COVID-19 and hereditary angioedema: Incidence, outcomes, and mechanistic implications.
Veronez CL, Christiansen SC, Smith TD, Riedl MA, Zuraw BL. Veronez CL, et al. Allergy Asthma Proc. 2021 Nov 1;42(6):506-514. doi: 10.2500/aap.2021.42.210083. Allergy Asthma Proc. 2021. PMID: 34871158 Free PMC article.
Background: Patients with hereditary angioedema (HAE) have been postulated to be at increased risk for coronavirus disease 2019 (COVID-19) infection due to inherent dysregulation of the plasma kallikrein-kinin system. ...Reported COVID-19 was reduced in the subjects …
Background: Patients with hereditary angioedema (HAE) have been postulated to be at increased risk for coronavirus disease 201 …
Racial and Ethnic Disparities in the Research and Care of Hereditary Angioedema Patients in the United States.
Sylvestre S, Craig T, Ajewole O, Craig S, Kaur S, Al-Shaikhly T. Sylvestre S, et al. J Allergy Clin Immunol Pract. 2021 Dec;9(12):4441-4449.e2. doi: 10.1016/j.jaip.2021.08.019. Epub 2021 Aug 28. J Allergy Clin Immunol Pract. 2021. PMID: 34464751 Free PMC article.
BACKGROUND: Hereditary angioedema (HAE) affects all races and both sexes equally. ...CONCLUSIONS: Clinical trials for Food and Drug Administration-approved HAE medications underrepresent minority patients. Hereditary angioedema remains underdiagnosed i …
BACKGROUND: Hereditary angioedema (HAE) affects all races and both sexes equally. ...CONCLUSIONS: Clinical trials for Food and …
Hereditary Angioedema with and Without C1-Inhibitor Deficiency in Postmenopausal Women.
Billebeau A, Fain O, Launay D, Boccon-Gibod I, Bouillet L, Gobert D, Plu-Bureau G, Gompel A; French National Reference Center for Hereditary Angioedema (CREAK). Billebeau A, et al. J Clin Immunol. 2021 Jan;41(1):163-170. doi: 10.1007/s10875-020-00902-7. Epub 2020 Oct 31. J Clin Immunol. 2021. PMID: 33130967
PURPOSE: Most types of hereditary angioedema (HAE) are worsened by endogenous or exogenous estrogens. ...HAE was associated with C1-INH deficiencyin 88% (n = 57) of the patients, a mutation of factor 12 in 8% (n = 5), a mutation in plasminogen gene in one, an …
PURPOSE: Most types of hereditary angioedema (HAE) are worsened by endogenous or exogenous estrogens. ...HAE was associated wi …
Healthcare utilization of patients with hereditary angioedema treated with lanadelumab and subcutaneous C1-inhibitor concentrate.
Riedl MA, Hinds DR, Prince PM, Alvord TM, Dosenovic S, Abdelhadi JF, Brownrigg JR, Camp CL, Machnig T, Banerji A. Riedl MA, et al. Allergy Asthma Proc. 2023 Jul 16;44(4):275-282. doi: 10.2500/aap.2023.44.230026. Epub 2023 Jun 16. Allergy Asthma Proc. 2023. PMID: 37328263
Background: New hereditary angioedema (HAE) treatments have become available in recent years for the treatment of HAE due to C1-inhibitor (C1-INH) deficiency, including two subcutaneous (SC) options: a monoclonal antibody (lanadelumab) and a plasma-derived C1-INH co …
Background: New hereditary angioedema (HAE) treatments have become available in recent years for the treatment of HAE due to C …
Development of the Hereditary Angioedema Rapid Triage Tool.
Betschel S, Avilla E, Kanani A, Kastner M, Keith P, Binkley K, Lacuesta G, Borici-Mazi R, Badiou J, Rowe A, Yang WH, Waserman S. Betschel S, et al. J Allergy Clin Immunol Pract. 2020 Jan;8(1):310-317.e3. doi: 10.1016/j.jaip.2019.05.056. Epub 2019 Jun 22. J Allergy Clin Immunol Pract. 2020. PMID: 31238160 Review.
BACKGROUND: Patients with hereditary angioedema (HAE) present to the emergency department (ED), where their symptoms are often incorrectly attributed to common allergic and gastrointestinal conditions, resulting in major delays in diagnosis and treatment. OBJECTIVE: …
BACKGROUND: Patients with hereditary angioedema (HAE) present to the emergency department (ED), where their symptoms are often …
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
At week 12, estimated treatment differences in mean CFB-UAS7 were as follows: for 72 mg ligelizumab versus placebo, -8.0 (95% CI -10.6 to -5.4; PEARL-1), -10.0 (-12.6 to -7.4; PEARL-2); 72 mg ligelizumab versus omalizumab 0.7 (-1.2 to 2.5; PEARL-1), 0.4 (-1.4 to 2.2; PEARL …
At week 12, estimated treatment differences in mean CFB-UAS7 were as follows: for 72 mg ligelizumab versus placebo, -8.0 (95% CI -10. …
Pharmacokinetics, Pharmacodynamics, and Exposure-Response of Lanadelumab for Hereditary Angioedema.
Wang Y, Marier JF, Kassir N, Chang C, Martin P. Wang Y, et al. Clin Transl Sci. 2020 Nov;13(6):1208-1216. doi: 10.1111/cts.12806. Epub 2020 May 26. Clin Transl Sci. 2020. PMID: 32407574 Free PMC article.
Hereditary angioedema (HAE) with C1 inhibitor deficiency is a rare disorder characterized by unpredictable, potentially life-threatening recurrent angioedema attacks. ...Population estimates of CL/F and V/F were 0.0249 L/hour (0.586 L/day) and 12.8 L, …
Hereditary angioedema (HAE) with C1 inhibitor deficiency is a rare disorder characterized by unpredictable, potentially life-t …
179 results